Personalized plan aims to cut opioid use in acute pain patients
NCT ID NCT05905146
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a personalized medication plan (PPP) can help patients with acute musculoskeletal pain stop taking strong opioids sooner, reducing the risk of dependence. Researchers will compare patients who receive the PPP during hospitalization to those who get standard care. The trial involves 200 participants and focuses on shortening opioid treatment duration.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- personalized pharmaceutical plan (educational interview)
- What this could lead to
- If it works, this could provide a simple way to reduce opioid dependence in people with short-term pain.
- What could go wrong
- This is a small, early-stage study with only 200 participants, so results may not apply broadly. The intervention is educational, not a drug, so benefits may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient hospitalized in the rheumatology department * Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology * Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion Exclusion Criteria: * Patient with cancer or fibromyalgia already diagnosed at inclusion * Patient with poor French language skills * Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion * Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment * Patient already included in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute pathology of the locomotor system are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Lille
RECRUITINGLille, France
-
CHU de Nimes
RECRUITINGNîmes, France
-
CHU de ROUEN
RECRUITINGRouen, France